Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Myung-Ju Ahn Kentaro Tanaka Luis G Paz-Ares Robin Cornelissen Nicolas Girard Elvire Pons-TostivintDavid Vicente BazShunichi Sugawara Manuel Cobo Maurice Pérol Céline Mascaux Elena V Poddubskaya Satoru Kitazono Hidetoshi Hayashi Min Hee Hong Enriqueta Felip Font Richard Hall Oscar Juan Vidal Daniel Brungs Shun Lu Marina-Chiara Garassino Michael J Chargualaf Yong Zhang Paul Howarth Deise Uema Aaron E Lisberg Jacob M Sandsnull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.

Keyphrases

phase iii
open label
small cell lung cancer
phase ii
clinical trial
double blind
squamous cell carcinoma
placebo controlled
phase ii study
study protocol
locally advanced
randomized controlled trial
rectal cancer